The ideas that fuel the research performed by ICN2 researchers may become an opportunity to create a new company. ICN2 is proactive in fostering entrepreneurial activities and spin-off creation. The Knowledge and Technology Transfer Department is committed to support such activities, either by participating in their development and by procuring information and educational tools to the ICN2 professionals.
To date, ICN2 has participated in the creation of 3 Spin Off companies, and its researchers have been involved in other projects managed by CSIC.
Nanotargeting S.L. is a start-up company coming from the Institut Català de Nanotecnologia and owned by Nanonica Europe S.L. with the mission to develop biomedical applications of nanotechnology.
Nanotargeting’s main project is Aurocis, which is a project born out of a Prof. Dr. Víctor Puntes’ idea jointly developed with Dr. Francisco Domínguez from Universidade de Santiago de Compostela, Dr. Fernando Romero from Universitat de València and Dr. Óscar Gallego from Hospital de la Santa Creu i Sant Pau. The results of the research carried out by Prof. Dr. Víctor Puntes and his colleagues are summarised in a patent application, whose rights have been acquired by Nanotargeting S.L. In addition, Nanotargeting S.L. has signed a strategic agreement with the Spanish pharmaceutical company, Grupo Ferrer S.A., to jointly develop the project.
The objective of this project is the use of gold nanoparticles to detoxify the antitumoral agent cisplatin linked to these nanoparticles via a pH sensitive coordination bond for endosomal release. Aurocis project is currently in preclinical development, and in vitro and in vivo studies have already proved cisplatin side effects reduction and pharmacokinetic improvement.
- FutureChromes S.L.
FutureChromes is a Spin Off company participated by ICN2 devoted to the creation of advanced photochromes.